COHERUS ONCOLOGY INC (CHRS:NASDAQ)
$1.33 -0.01 (-0.7463%)
Analysed COHERUS ONCOLOGY INC (CHRS:NASDAQ) News Sources
Coherus Oncology, Inc. Q1 2026 Earnings Call Summary
12-05-2026
moby.co
Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors
11-06-2026
yahoo.com
What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today
14-05-2026
yahoo.com
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
23-06-2026
yahoo.com
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
22-07-2026
yahoo.com
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
05-08-2026
yahoo.com
Coherus Oncology Q2 Earnings Call Highlights
06-08-2026
marketbeat.com
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ...
06-08-2026
yahoo.com
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript
13-08-2026
fool.com
Coherus to Participate in Upcoming Investor Conferences
31-08-2026
yahoo.com
What is the current price of COHERUS ONCOLOGY INC (CHRS:NASDAQ)?
The current price of COHERUS ONCOLOGY INC (CHRS:NASDAQ) is $1.33.
COHERUS ONCOLOGY INC (CHRS:NASDAQ) absolute price change since previous trading day?
The absolute price change of COHERUS ONCOLOGY INC (CHRS:NASDAQ) since the previous trading day is $-0.01.
COHERUS ONCOLOGY INC (CHRS:NASDAQ) percentage price change since previous trading day?
The percentage price change of COHERUS ONCOLOGY INC (CHRS:NASDAQ) since the previous trading day is -0.7463%.
What is the most recent average sentiment score for COHERUS ONCOLOGY INC (CHRS:NASDAQ)?
The most recent average sentiment score for COHERUS ONCOLOGY INC (CHRS:NASDAQ) is 51 out of 100.
What is the most recent average sentiment for COHERUS ONCOLOGY INC (CHRS:NASDAQ)?
The most recent sentiment for COHERUS ONCOLOGY INC (CHRS:NASDAQ) is .
SEC-8K** Filing Available For COHERUS ONCOLOGY INC (CHRS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.